KCM
LGND icon

Kornitzer Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Kornitzer Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Hold
60,342
– – 0.26% 85
2025
Q4 		$11.4M Sell
60,342
-30,825
-34% -$5.92M 0.24% 97
2025
Q3 		$16.1M Hold
91,167
– – 0.32% 71
2025
Q2 		$10.4M Sell
91,167
-44,315
-33% -$4.74M 0.21% 126
2025
Q1 		$14.2M Hold
135,482
– – 0.29% 86
2024
Q4 		$14.5M Hold
135,482
– – 0.28% 92
2024
Q3 		$13.6M Hold
135,482
– – 0.25% 116
2024
Q2 		$11.4M Hold
135,482
– – 0.22% 134
2024
Q1 		$9.9M Hold
135,482
– – 0.18% 172
2023
Q4 		$9.68M Hold
135,482
– – 0.19% 176
2023
Q3 		$8.12M Hold
135,482
– – 0.17% 194
2023
Q2 		$9.77M Hold
135,482
– – 0.19% 174
2023
Q1 		$9.97M Buy
135,482
+28,730
+27% +$2.04M 0.2% 164
2022
Q4 		$7.13M Sell
106,752
-94,732
-47% -$6.16M 0.14% 218
2022
Q3 		$10.8M Sell
201,484
-151,852
-43% -$8.93M 0.23% 144
2022
Q2 		$19.7M Sell
353,336
-133,049
-27% -$7.55M 0.39% 72
2022
Q1 		$34.1M Hold
486,385
– – 0.56% 39
2021
Q4 		$46.9M Hold
486,385
– – 0.7% 23
2021
Q3 		$42.3M Sell
486,385
-52,539
-10% -$4.06M 0.65% 25
2021
Q2 		$44.1M Sell
538,924
-109,930
-17% -$9.14M 0.66% 26
2021
Q1 		$61.7M Sell
648,854
-58,374
-8% -$5.52M 0.99% 5
2020
Q4 		$43.9M Buy
707,228
+60,979
+9% +$3.48M 0.74% 23
2020
Q3 		$38.4M Buy
646,249
+73,048
+13% +$4.98M 0.75% 24
2020
Q2 		$40M Buy
573,201
+348,500
+155% +$22.1M 0.81% 17
2020
Q1 		$10.2M Buy
224,701
+54,310
+32% +$3.08M 0.24% 143
2019
Q4 		$11.1M Sell
170,391
-18,383
-10% -$1.23M 0.2% 161
2019
Q3 		$11.7M Buy
188,774
+11,221
+6% +$704K 0.21% 146
2019
Q2 		$12.6M Sell
177,553
-7,518
-4% -$554K 0.22% 141
2019
Q1 		$14.5M Buy
185,071
+36,362
+24% +$2.75M 0.26% 129
2018
Q4 		$12.6M Buy
148,709
+44,783
+43% +$4.77M 0.25% 131
2018
Q3 		$17.8M Sell
103,926
-15,068
-13% -$2.27M 0.28% 125
2018
Q2 		$15.4M Sell
118,994
-1,592
-1% -$178K 0.26% 126
2018
Q1 		$12.4M Sell
120,586
-30,713
-20% -$3.04M 0.21% 142
2017
Q4 		$12.9M Sell
151,299
-6,877
-4% -$596K 0.22% 139
2017
Q3 		$13.4M Sell
158,176
-26,979
-15% -$2.14M 0.23% 133
2017
Q2 		$14M Buy
185,155
+84,062
+83% +$5.88M 0.25% 130
2017
Q1 		$6.67M Buy
101,093
+817
+0.8% +$53.7K 0.12% 227
2016
Q4 		$6.36M Sell
100,276
-8,504
-8% -$537K 0.12% 225
2016
Q3 		$6.93M Buy
+108,780
New +$7.99M 0.12% 222

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Kornitzer Capital Management's LGND Position: Q1 2026 in Review

Kornitzer Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 60,342 shares worth $12M. The position accounts for 0.26% of the portfolio, ranked #85.

Kornitzer Capital Management first reported a position in LGND in Q3 2016 and has held it in 39 quarters since. The position peaked at $61.7M in Q1 2021. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Kornitzer Capital Management held 60,342 shares of Ligand Pharmaceuticals worth $12M as of Q1 2026.
  • Kornitzer Capital Management left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.26% of Kornitzer Capital Management's portfolio in Q1 2026, its #85 holding.
  • Kornitzer Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 39 quarters since.
  • Kornitzer Capital Management's Ligand Pharmaceuticals position peaked at $61.7M in Q1 2021.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Kornitzer Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.